Advanced search
Publication Cover
Expert Opinion on Drug Metabolism & Toxicology Volume 2, 2006 - Issue 5
Submit an article Journal homepage
364
Views
48
CrossRef citations to date
0
Altmetric
Review

Genetic polymorphisms of drug transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy

Ichiro Ieiri Associate Professor, Kyushu University, Department of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Maidashi 3-1-1, Higashi-ku, Fukuoka, 812-8582, Japan. [email protected]
,
Hiroshi Takane Chief Pharmacist, Tottori University Hospital, Department of Clinical Pharmacy, Yonago, 683-8504, Japan
,
Takeshi Hirota Assistant Professor, Kyushu University, Department of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Maidashi 3-1-1, Higashi-ku, Fukuoka, 812-8582, Japan
,
Kenji Otsubo Professor, Tottori University Hospital, Department of Clinical Pharmacy, Yonago, 683-8504, Japan
&
Shun Higuchi Professor, Kyushu University, Department of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Maidashi 3-1-1, Higashi-ku, Fukuoka, 812-8582, Japan
Pages 651-674 | Published online: 03 Oct 2006

Bibliography

  • CORDON-CARDO C, O’BRIEN JP, BOCCIA J, CASALS D, BERTINO JR, MELAMED MR: Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem. (1990) 38:1277-1287.
  • THIEBAUT F, TSURUO T, HAMADA H, GOTTESMAN MM, PASTAN I, WILLINGHAM MC: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA (1987) 84:7735-7738.
  • FOJO AT, UEDA K, SLAMON DJ, POPLACK DG, GOTTESMAN MM, PASTAN I: Expression of a multidrug-resistance gene in human tumors and tissues. Proc. Natl. Acad. Sci. USA (1987) 84:265-269.
  • SUGAWARA I, KATAOKA I, MORISHITA Y etal.: Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res. (1988) 48:1926-1929.
  • KIM RB, FROMM MF, WANDEL C etal.: The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. (1998) 101:289-294.
  • MAYER U, WAGENAAR E, BEIJNEN JH etal.: Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein. Br. J. Pharmacol. (1996) 119:1038-1044.
  • NAKAMURA Y, IKEDA S, FURUKAWA T etal.: Function of P-glycoprotein expressed in placenta and mole. Biochem. Biophys. Res. Commun. (1997) 235:849-853.
  • SCHINKEL AH, WAGENAAR E, MOL CA, VAN DEEMTER L: P-glycoprotein in the blood–brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. (1996) 97:2517-2524.
  • CORDON-CARDO C, O’BRIEN JP, CASALS D etal.: Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood–brain barrier sites. Proc. Natl. Acad. Sci. USA (1989) 86:695-698.
  • VAN DE WATER FM, MASEREEUW R, RUSSEL FG: Function and regulation of multidrug resistance proteins (MRPs) in the renal elimination of organic anions. Drug Metab. Rev. (2005) 37:443-471.
  • SUZUKI H, SUGIYAMA Y: Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. Adv. Drug Deliv. Rev. (2002) 54:1311-1331.
  • BUCHLER M, KONIG J, BROM M etal.: cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. J. Biol. Chem. (1996) 271:15091-15098.
  • PAULUSMA CC, BOSMA PJ, ZAMAN GJ etal.: Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science (1996) 271:1126-1128.
  • SCHAUB TP, KARTENBECK J, KONIG J etal.: Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma. J. Am. Soc. Nephrol. (1999) 10:1159-1169.
  • MOTTINO AD, HOFFMAN T, JENNES L, VORE M: Expression and localization of multidrug resistant protein mrp2 in rat small intestine. J. Pharmacol. Exp. Ther. (2000) 293:717-723.
  • CERVENAK J, ANDRIKOVICS H, OZVEGY-LACZKA C etal.: The role of the human ABCG2 multidrug transporter and its variants in cancer therapy and toxicology. Cancer Lett. (2006) 234:62-72.
  • MALIEPAARD M, SCHEFFER GL, FANEYTE IF etal.: Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. (2001) 61:3458-3464.
  • KRUIJTZER CM, BEIJNEN JH, SCHELLENS JH: Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview. Oncologist (2002) 7:516-530.
  • TAIPALENSUU J, TORNBLOM H, LINDBERG G etal.: Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J. Pharmacol. Exp. Ther. (2001) 299:164-170.
  • STAUD F, PAVEK P: Breast cancer resistance protein (BCRP/ABCG2). Int. J. Biochem. Cell Biol. (2005) 37:720-725.
  • XU J, LIU Y, YANG Y, BATES S, ZHANG JT: Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2. J. Biol. Chem. (2004) 279:19781-19789.
  • DOYLE AL, YANG W, ABRUZZO LV etal.: A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA (1998) 95:15665-15670.
  • KAGE K, TSUKAHARA S, SUGIYAMA T etal.: Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization. Int. J. Cancer (2002) 97:626-630.
  • ROSS DD: Novel mechanisms of drug resistance in leukemia. Leukemia (2000) 14:467-473.
  • KULLAK-UBLICK GA, HAGENBUCH B, STIEGER B etal.: Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology (1995) 109:1274-1282.
  • SMITH LH, LEE W, KIM RB: Differential expression of OATP drug uptake transporters in human liver, intestine, and kidney. Drug Metab. Rev. (2003) 35:73.
  • DRESSER GK, KIM RB, BAILEY DG: Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides. Clin. Pharmacol. Ther. (2005) 77:170-177.
  • TAMAI I, NEZU J, UCHINO H etal.: Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem. Biophys. Res. Commun. (2000) 273:251-260.
  • ABE T, KAKYO M, TOKUI T etal.: Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J. Biol. Chem. (1999) 274:17159-17163.
  • HSIANG B, ZHU Y, WANG Z etal.: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J. Biol. Chem. (1999) 274:37161-37168.
  • KONIG J, CUI Y, NIES AT, KEPPLER D: Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J. Biol. Chem. (2000) 275:23161-23168.
  • NOZAWA T, IMAI K, NEZU J, TSUJI A, TAMAI I: Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J. Pharmacol. Exp. Ther. (2004) 308:438-445.
  • KULLAK-UBLICK GA, ISMAIR MG, STIEGER B etal.: Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology (2001) 120:525-533.
  • SEKINE T, WATANABE N, HOSOYAMADA M, KANAI Y, ENDOU H: Expression cloning and characterization of a novel multispecific organic anion transporter. J. Biol. Chem. (1997) 272:18526-18529.
  • DRESSER MJ, LEABMAN MK, GIACOMINI KM: Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters. J. Pharm. Sci. (2001) 90:397-421.
  • MIYAZAKI H, SEKINE T, ENDOU H: The multispecific organic anion transporter family: properties and pharmacological significance. Trends Pharmacol. Sci. (2004) 25:654-662.
  • ENDOU H: Recent advances in molecular mechanisms of nephrotoxicity. Toxicol. Lett. (1998) 102-103:29-33.
  • CIHLAR T, LIN DC, PRITCHARD JB, FULLER MD, MENDEL DB, SWEET DH: The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol. Pharmacol. (1999) 56:570-580.
  • HO ES, LIN DC, MENDEL DB, CIHLAR T: Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J. Am. Soc. Nephrol. (2000) 11:383-393.
  • JARIYAWAT S, SEKINE T, TAKEDA M etal.: The interaction and transport of β-lactam antibiotics with the cloned rat renal organic anion transporter 1. J. Pharmacol. Exp. Ther. (1999) 290:672-677.
  • SIMONSON GD, VINCENT AC, ROBERG KJ, HUANG Y, IWANIJ V: Molecular cloning and characterization of a novel liver-specific transport protein. J. Cell Sci. (1994) 107:1065-1072.
  • SEKINE T, CHA SH, TSUDA M etal.: Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett. (1998) 429:179-182.
  • NAGATA Y, KUSUHARA H, ENDOU H, SUGIYAMA Y: Expression and functional characterization of rat organic anion transporter 3 (rOat3) in the choroid plexus. Mol. Pharmacol. (2002) 61:982-988.
  • SWEET DH, MILLER DS, PRITCHARD JB, FUJIWARA Y, BEIER DR, NIGAM SK: Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice. J. Biol. Chem. (2002) 277:26934-26943.
  • JONKER JW, SCHINKEL AH: Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J. Pharmacol. Exp. Ther. (2004) 308:2-9.
  • BURCKHARDT G, WOLFF NA: Structure of renal organic anion and cation transporters. Am. J. Physiol. Renal Physiol. (2000) 278:F853-F866.
  • ZHANG L, DRESSER MJ, GRAY AT, YOST SC, TERASHITA S, GIACOMINI KM: Cloning and functional expression of a human liver organic cation transporter. Mol. Pharmacol. (1997) 51:913-921.
  • GORBOULEV V, ULZHEIMER JC, AKHOUNDOVA A etal.: Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. (1997) 16:871-881.
  • VERHAAGH S, SCHWEIFER N, BARLOW DP, ZWART R: Cloning of the mouse and human solute carrier 22a3 (Slc22a3/SLC22A3) identifies a conserved cluster of three organic cation transporters on mouse chromosome 17 and human 6q26-q27. Genomics (1999) 55:209-218.
  • SCHWAB M, EICHELBAUM M, FROMM MF: Genetic polymorphisms of the human MDR1 drug transporter. Ann. Rev. Pharmacol. Toxicol. (2003) 43:285-307.
  • FROMM MF: The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv. Drug Deliv. Rev. (2002) 54:1295-1310.
  • KIM RB: Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab. Rev. (2002) 34:47-54.
  • WACHER VJ, WU CY, BENET LZ: Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog. (1995) 13:129-134.
  • KIM RB, WANDEL C, LEAKE B etal.: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm. Res. (1999) 16:408-414.
  • JEDLITSCHKY G, LEIER I, BUCHHOLZ U, BARNOUIN K, KURZ G, KEPPLER D: Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res. (1996) 56:988-994.
  • PRIEBE W, KRAWCZYK M, KUO MT, YAMANE Y, SAVARAJ N, ISHIKAWA T: Doxorubicin- and daunorubicin-glutathione conjugates, but not unconjugated drugs, competitively inhibit leukotriene C4 transport mediated by MRP/GS-X pump. Biochem. Biophys. Res. Commun. (1998) 247:859-863.
  • BAKOS E, EVERS R, SINKO E, VARADI A, BORST P, SARKADI B: Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol. Pharmacol. (2000) 57:760-768.
  • ISHIKAWA T: The ATP-dependent glutathione S-conjugate export pump. Trends Biochem. Sci. (1992) 17:463-468.
  • LOE DW, ALMQUIST KC, DEELEY RG, COLE SP: Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. J. Biol. Chem. (1996) 271:9675-9682.
  • JONKER JW, SMIT JW, BRINKHUIS RF etal.: Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J. Natl. Cancer Inst. (2000) 92:1651-1656.
  • SUZUKI M, SUZUKI H, SUGIMOTO Y, SUGIYAMA Y: ABCG2 transports sulfated conjugates of steroids and xenobiotics. J. Biol. Chem. (2003) 278:22644-22649.
  • BORST P, EVERS R, KOOL M, WIJNHOLDS J: A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. (2000) 92:1295-1302.
  • LITMAN T, BRANGI M, HUDSON E etal.: The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J. Cell Sci. (2000) 113:2011-2021.
  • ECKHARDT U, SCHROEDER A, STIEGER B etal.: Polyspecific substrate uptake by the hepatic organic anion transporter Oatp1 in stably transfected CHO cells. Am. J. Physiol. (1999) 276:G1037-G1042.
  • CVETKOVIC M, LEAKE B, DROMM MF, WILKINSON GR, KIM RB: OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos. (1999) 27:866-871.
  • GAO B, HAGENBUCH B, KULLAK-UBLICK GA, BENKE D, AGUZZI A, MEIER PJ: Organic anion-transporting polypeptides mediate transport of opioid peptides across blood–brain barrier. J. Pharmacol. Exp. Ther. (2000) 294:73-79.
  • CUI Y, KONIG J, LEIER I, BUCHHOLZ U, KEPPLER D: Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J. Biol. Chem. (2001) 276:9626-9630.
  • NAKAI D, NAKAGOMI R, FURUTA Y etal.: Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J. Pharmacol. Exp. Ther. (2001) 297:861-867.
  • CHUNG JY, CHO JY, YU KS etal.: Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin. Pharmacol. Ther. (2005) 78:342-350.
  • ABE T, UNNO M, ONOGAWA T etal.: LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology (2001) 120:1689-1699.
  • UWAI Y, OKUDA M, TAKAMI K, HASHIMOTO Y, INUI K: Functional characterization of the rat multispecific organic anion transporter OAT1 mediating basolateral uptake of anionic drugs in the kidney. FEBS Lett. (1998) 438:321-324.
  • APIWATTANAKUL N, SEKINE T, CHAIROUNGDUA A etal.: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol. Pharmacol. (1999) 55:847-854.
  • MORITA N, KUSUHARA H, SEKINE T, ENDOU H, SUGIYAMA Y: Functional characterization of rat organic anion transporter 2 in LLC-PK1 cells. J. Pharmacol. Exp. Ther. (2001) 298:1179-1184.
  • GOTTESMAN MM, HRYCYNA CA, SCHOENLEIN PV, GERMANN UA, PASTAN I: Genetic analysis of the multidrug transporter. Ann. Rev. Genet. (1995)　29:607-649.
  • BODOR M, KELLY EJ, HO RJ: Characterization of the human MDR1 gene. AAPS J. (2005) 7:E1-E5.
  • MICKLEY LA, LEE JS, WENG Z etal.: Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. Blood (1998) 91:1749-1756.
  • HOFFMEYER S, BURK O, VON RICHTER O etal.: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA (2000) 97:3473-3478.
  • TANABE M, IEIRI I, NAGATA N etal.: Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J. Pharmacol. Exp. Ther. (2001) 297:1137-1143.
  • ITO S, IEIRI I, TANABE M, SUZUKI A, HIGUCHI S, OTSUBO K: Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics (2001) 11:175-184.
  • CASCORBI I, GERLOFF T, JOHNE A etal.: Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin. Pharmacol. Ther. (2001) 69:169-174.
  • KIM RB, LEAKE BF, CHOO EF etal.: Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. (2001) 70:189-199.
  • IEIRI I, TAKANE H, OTSUBO K: The MDR1 (ABCB1) gene polymorphism and its clinical implications. Clin. Pharmacokinet. (2004) 43:553-576.
  • TANG K, NGOI SM, GWEE PC etal.: Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics (2002) 12:437-450.
  • CHOWBAY B, CUMARASWAMY S, CHEUNG YB, ZHOU Q, LEE EJ: Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics (2003) 13:89-95.
  • KROETZ DL, PAULI-MAGNUS C, HODGES LM etal.; PHARMACOGENETICS OF MEMBRANE TRANSPORTERS INVESTIGATORS: Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics (2003) 13:481-494.
  • SAI K, KANIWA N, ITODA M etal.: Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics (2003) 13:741-757.
  • AMEYAW MM, REGATEIRO F, LI T etal.: MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics (2001) 11:217-221.
  • LINDHOLM A, WELSH M, ALTON C, KAHAN BD: Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: racial differences in bioavailability. Clin. Pharmacol. Ther. (1992) 52:359-371.
  • MANCINELLI LM, FRASSETTO L, FLOREN LC etal.: The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin. Pharmacol. Ther. (2001) 69:24-31.
  • ELMORE JG, MOCERI VM, CARTER D, LARSON EB: Breast carcinoma tumor characteristics in black and white women. Cancer (1998) 83:2509-2515.
  • TSUJII H, KONIG J, ROST D, STOCKEL B, LEUSCHNER U, KEPPLER D: Exon-intron organization of the human multidrug-resistance protein 2 (MRP2) gene mutated in Dubin–Johnson syndrome. Gastroenterology (1999) 117:653-660.
  • TOH S, WADA M, UCHIUMI T etal.: Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin–Johnson syndrome. Am. J. Hum. Genet. (1999) 64:739-746.
  • WADA M: Single nucleotide polymorphisms in ABCC2 and ABCB1 genes and their clinical impact in physiology and drug response. Cancer Lett. (2006) 234:40-50.
  • ALLIKMETS R, SCHRIML LM, HUTCHINSON A, ROMANO-SPICA V, DEAN M: A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res. (1998) 58:5337-5339.
  • IIDA A, SAITO S, SEKINE A etal.: Catalog of 605 single-nucleotide polymorphisms (SNPs) among 13 genes encoding human ATP-binding cassette transporters: ABCA4, ABCA7, ABCA8, ABCD1, ABCD3, ABCD4, ABCE1, ABCF1, ABCG1, ABCG2, ABCG4, ABCG5, and ABCG8. J. Hum. Genet. (2002) 47:285-310.
  • ZAMBER CP, LAMBA JK, YASUDA K etal.: Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics (2003) 13:19-28.
  • KOBAYASHI D, IEIRI I, HIROTA T etal.: Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab. Dispos. (2005) 33:94-101.
  • BACKSTROM G, TAIPALENSUU J, MELHUS H etal.: Genetic variation in the ATP-binding cassette transporter gene ABCG2 (BCRP) in a Swedish population. Eur. J. Pharm. Sci. (2003) 18:359-364.
  • IIDA A, SAITO S, SEKINE A etal.: Catalog of 258 single-nucleotide polymorphisms (SNPs) in genes encoding three organic anion transporters, three organic anion-transporting polypeptides, and three NADH:ubiquinone oxidoreductase flavoproteins. J. Hum. Genet. (2001) 46:668-683.
  • LEE W, GLAESER H, SMITH LH etal.: Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J. Biol. Chem. (2005) 280:9610-9617.
  • TIRONA RG, LEAKE BF, MERINO G, KIM RB: Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J. Biol. Chem. (2001) 276:35669-35675.
  • NIEMI M, SCHAEFFELER E, LANG T etal.: High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics (2004) 14:429-440.
  • NISHIZATO Y, IEIRI I, SUZUKI H etal.: Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Ther. (2003) 73:554-565.
  • MWINYI J, JOHNE A, BAUER S, ROOTS I, GERLOFF T: Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin. Pharmacol. Ther. (2004) 75:415-421.
  • TAKANE H, MIYATA M, BURIOKA N etal.: Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy. J. Hum Genet. (2006) (In Press).
  • FUJITA T, BROWN C, CARLSON EJ etal.: Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1). Pharmacogenet. Genomics (2005) 15:201-209.
  • XU G, BHATNAGAR V, WEN G, HAMILTON BA, ERALY SA, NIGAM SK: Analyses of coding region polymorphisms in apical and basolateral human organic anion transporter (OAT) genes [OAT1 (NKT), OAT2, OAT3, OAT4, URAT (RST)]. Kidney Int. (2005) 68:1491-1499.
  • ITODA M, SAITO Y, MAEKAWA K etal.: Seven novel single nucleotide polymorphisms in the human SLC22A1 gene encoding organic cation transporter 1 (OCT1). Drug Metab. Pharmacokinet. (2004) 19:308-312.
  • SHU Y, LEABMAN MK, FENG B etal.; PHARMACOGENETICS OF MEMBRANE TRANSPORTERS INVESTIGATORS: Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc. Natl. Acad. Sci. USA (2003) 100:5902-5907.
  • KERB R, BRINKMANN U, CHATSKAIA N etal.: Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics (2002) 12:591-595.
  • FUKUSHIMA-UESAKA H, MAEKAWA K, OZAWA S etal.: Fourteen novel single nucleotide polymorphisms in the SLC22A2 gene encoding human organic cation transporter (OCT2). Drug Metab. Pharmacokinet. (2004) 19:239-244.
  • LEABMAN MK, HUANG CC, KAWAMOTO M etal.; PHARMACOGENETICS OF MEMBRANE TRANSPORTERS INVESTIGATORS: Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics (2002) 12:395-405.
  • SAITO S, IIDA A, SEKINE A etal.: Catalog of 238 variations among six human genes encoding solute carriers (hSLCs) in the Japanese population. J. Hum. Genet. (2002) 47:576-584.
  • SAKAEDA T: MDR1 genotype-related pharmacokinetics: fact or fiction? Drug Metab. Pharmacokinet. (2005) 20:391-414.
  • PAULI-MAGNUS C, KROETZ DL: Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1). Pharm. Res. (2004) 21:904-913.
  • MARZOLINI C, PAUS E, BUCLIN T, KIM RB: Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. (2004) 75:13-33.
  • SAKAEDA T, NAKAMURA T, HORINOUCHI M etal.: MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm. Res. (2001) 18:1400-1404.
  • KURATA Y, IEIRI I, KIMURA M etal.: Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin. Pharmacol. Ther. (2002) 72:209-219.
  • JOHNE A, KOPKE K, GERLOFF T etal.: Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin. Pharmacol. Ther. (2002) 72:584-594.
  • WANG D, JOHNSON AD, PAPP AC, KROETZ DL, SADEE W: Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C > T affects mRNA stability. Pharmacogenet. Genomics (2005) 15:693-704.
  • HIROTA T, IEIRI I, TAKANE H et al.: Allelic expression imbalance of the human CYP3A4 gene and individual phenotypic status. Hum. Mol. Genet. (2004) 13:2959-2969.
  • WOJNOWSKI L, BROCKMOLLER J: Single nucleotide polymorphism characterization by mRNA expression imbalance assessment. Pharmacogenetics (2004) 14:267-269.
  • BRUNNER M, LANGER O, SUNDER-PLASSMANN R etal.: Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans. Clin. Pharmacol. Ther. (2005) 78:182-190.
  • HENDRIKSE NH, DE VRIES EG, ERIKS-FLUKS L etal.: A new in vivo method to study P-glycoprotein transport in tumors and the blood–brain barrier. Cancer Res. (1999) 59:2411-2416.
  • SPARREBOOM A, GELDERBLOM H, MARSH S etal.: Diflomotecan pharmacokinetics in relation to ABCG2 421C > A genotype. Clin. Pharmacol. Ther. (2004) 76:38-44.
  • IMAI Y, NAKANE M, KAGE K etal.: C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol. Cancer Ther. (2002) 1:611-616.
  • KONDO C, SUZUKI H, ITODA M etal.: Functional analysis of SNPs variants of BCRP/ABCG2. Pharm. Res. (2004) 21:1895-1903.
  • SPARREBOOM A, LOOS WJ, BURGER H etal.: Effect of ABCG2 genotype on the oral bioavailability of topotecan. Cancer Biol. Ther. (2005) 4:650-658.
  • DE JONG FA, MARSH S, MATHIJSSEN RH etal.: ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin. Cancer Res. (2004) 10:5889-5894.
  • OLOMBO S, SORANZO N, ROTGER M etal.: Influence of ABCB1, ABCC1, ABCC2, and ABCG2 heplotypes on the cellular exposure of nelfinavir in vivo. Pharmacogenet. Genomics (2005) 15:599-608.
  • SEKINO H, ONOSHI T, SEKINO H: Phase I study of ZD-4522 (rosuvastatin), a new HMG-CoA reductase inhibitor-evaluation of tolerance and pharmacokinetics in healthy adult male volunteers after single and repeated oral administration. J. Clin. Ther. Med. (2005) 21:187-203.
  • WARWICK MJ, DANE AL, RAZA A, ACHNECK DW: Single and multiple-dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD-4522 [abstract]. Atherosclerosis (2000) 151:39.
  • MARTIN PD, MITCHELL PD, SCHNECK DW: Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br. J. Clin. Pharmacol. (2002) 54:472-477.
  • SIMONSON SG, RAZA A, MARTIN PD etal.: Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin. Pharmacol. Ther. (2004) 76:167-177.
  • LEE E, RYAN S, BIRMINGHAM B etal.: Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin. Pharmacol. Ther. (2005) 78:330-341.
  • TIRONA RG: Ethnic differences in statin disposition. Clin. Pharmacol. Ther. (2005) 78:311-316.
  • NIEMI M, KIVISTO KT, HOFMANN U, SCHWAB M, EICHELBAUM M, FROMM MF: Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br. J. Clin. Pharmacol. (2005) 59:602-604.
  • NIEMI M, BACKMAN JT, KAJOSAARI LI etal.: Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin. Pharmacol. Ther. (2005) 77:468-478.
  • MAEDA K, IEIRI I, YASUDA K etal.: Effects of OATP1B1 haplotype on pharmacokinetics of pravastatin, valsartan and temocapril. Clin. Pharmacol. Ther. (2006) 79:427-439.
  • KAMEYAMA Y, YAMASHITA K, KOBAYASHI K, HOSOKAWA M, CHIBA K: Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet. Genomics (2005) 15:513-522.
  • IWAI M, SUZUKI H, IEIRI I, OTSUBO K, SUGIYAMA Y: Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenet. Genomics (2004) 14:749-757.
  • LEABMAN M, BROWN C, CHUNG J etal.: Heritability of metformin renal clearance. Clin. Pharmacol. Ther (2005) 77:P61.
  • FELLAY J, MARZOLINI C, MEADEN ER etal.: Swiss HIV Cohort Study. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet (2002) 359:30-36.
  • HAAS DW, SMEATON LM, SHAFER RW etal.: Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an Adult Aids Clinical Trials Group Study. J. Infect. Dis. (2005) 192:1931-1942.
  • NASI M, BORGHI V, PINTI M etal.: MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients. AIDS (2003) 17:1696-1698.
  • WINZER R, LANGMANN P, ZILLY M etal.: No influence of the P-glycoprotein polymorphisms MDR1 G2677T/A and C3435T on the virological and immunological response in treatment naive HIV-positive patients. Ann. Clin. Microbiol. Antimicrob. (2005) 4:1-7.
  • LOSCHER W, POTSCHKA H: Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J. Pharmacol. Exp. Ther. (2002) 301:7-14.
  • TISHLER DM, WEINBERG KI, HINTON DR, BARBARO N, ANNETT GM, RAFFEL C: MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia (1995) 36:1-6.
  • SISODIYA SM, LIN WR, SQUIER MV, THOM M: Multidrug-resistance protein 1 in focal cortical dysplasia. Lancet (2001) 357:42-43.
  • SISODIYA SM, LIN WR, HARDING BN, SQUIER MV, THOM M: Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain (2002) 125:22-31.
  • DOMBROWSKI SM, DESAI SY, MARRONI M etal.: Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia (2001) 42:1501-1506.
  • SIDDIQUI A, KERB R, WEALE MR etal.: Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N. Engl. J. Med. (2003) 348:1442-1448.
  • TAN NC, HERON SE, SCHEFFER IE etal.: Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy. Neurology (2004) 63:1090-1092.
  • SILLS GJ, MOHANRAJ R, BUTLER E etal.: Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia (2005) 46:643-647.
  • ILLMER T, SCHULER US, THIEDW C etal.: MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res. (2002) 62:4955-4962.
  • VAN DEN HEUVEL-EIBRINK MM, WIEMER EA, DE BOEVERE MJ etal.: MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia. Blood (2001) 97:3605-3611.
  • EFFERTH T, SAUERBREY A, STEINBACH D etal.: Analysis of single nucleotide polymorphism C3435T of the multidrug resistance gene MDR1 in acute lymphoblastic leukemia. Int. J. Oncol. (2003) 23:509-517.
  • GOREVA OB, GRISHANOVA AY, MUKHIN OV, DOMNIKOVA NP, LYAKHOVICH VV: Possible prediction of the efficiency of chemotherapy in patients with lymphoproliferative diseases based on MDR1 gene G2677T and C3435T polymorphisms. Bull. Exp. Biol. Med. (2003) 136:183-185.
  • ISLA D, SARRIES C, ROSELL R etal.: Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann. Oncol. (2004) 15:1194-1203.
  • PLASSCHAERT SL, GRONINGER E, BOEZEN M etal.: Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. Clin. Pharmacol. Ther. (2004) 76:220-229.
  • YAMAUCHI A, IEIRI I, KATAOKA Y etal.: Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation (2002) 74:571-572.
  • HAUSER IA, SCHAEFFELER E, GAUER S etal.: ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J. Am. Soc. Nephrol. (2005) 16:1501-1511.
  • DROZDZIK M, MYSLIWIEC K, LEWINSKA-CHELSTOWSKA M, BANACH J, DROZDZIK A, GRABAREK J: P-glycoprotein drug transporter MDR1 gene polymorphism in renal transplant patients with and without gingival overgrowth. J. Clin. Periodontol. (2004) 31:758-763.
  • FURUNO T, LANDI MT, CERONI M etal.: Expression polymorphism of the blood–brain barrier component P-glycoprotein (MDR1) in relation to Parkinson’s disease. Pharmacogenetics (2002) 12:529-534.
  • DROZDZIK M, BIALECKA M, MYSLIWIEC K, HONCZARENKO K, STANKIEWICZ J, SYCH Z: Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson’s disease. Pharmacogenetics (2003) 13:259-263.
  • TAN EK, DROZDZIK M, BIALECKA M etal.: Analysis of MDR1 haplotypes in Parkinson’s disease in a white population. Neurosci. Lett. (2004) 372:240-244.
  • TAN EK, CHAN DK, NG PW etal.: Effect of MDR1 haplotype on risk of Parkinson’s disease. Arch. Neurol. (2005) 62:460-464.
  • SCHWAB M, SCHAEFFELER E, MARX C etal.: Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology (2003) 124:26-33.
  • CROUCHER PJ, MASCHERETTI S, FOELSCH UR, HAMPE J, SCHREIBER S: Lack of association between the C3435T MDR1 gene polymorphism and inflammatory bowel disease in two independent Northern European populations. Gastroenterology (2003) 125:1919-1920.
  • BRANT SR, PANHUYSEN CI, NICOLAE D etal.: MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am. J. Hum. Genet. (2003) 73:1282-1292.
  • GAZOULI M, ZACHARATOS P, GORGOULIS V, MANTZARIS G, PAPALAMBROS E, IKONOMOPOULOS J: The C3435T MDR1 gene polymorphism is not associated with susceptibility for ulcerative colitis in Greek population. Gastroenterology (2004) 126:367-369.
  • GLAS J, TOROK HP, SCHIEMANN U, FOLWACZNY C: MDR1 gene polymorphism in ulcerative colitis. Gastroenterology (2004) 126:367.
  • POTOCNIK U, FERKOLJ I, GLAVAC D, DEAN M: Polymorphisms in multidrug resistance 1 (MDR1) gene are associated with refractory Crohn disease and ulcerative colitis. Genes Immun. (2004) 5:530-539.
  • HO GT, NIMMO ER, TENESA A etal.: Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis. Gastroenterology (2005) 128:288-296.
  • URCELAY E, MENDOZA JL, MARTIN MC etal.: MDR1 gene: susceptibility in Spanish Crohn’s disease and ulcerative colitis patients. Inflamm. Bowel Dis. (2006) 12:33-37.
  • JAMROZIAK K, MLYNARSKI W, BALCERCZAK E etal.: Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur. J. Haematol. (2004) 72:314-321.
  • STANULLA M, SCHAFFELER E, ARENS S etal.: GSTP1 and MDR1 genotypes and central nervous system relapse in childhood acute lymphoblastic leukemia. Int. J. Hematol. (2005) 81:39-44.
  • POTOCNIK U, RAVNIK-GLAVAC M, GOLOUH R, GLAVAC D: Naturally occurring mutations and functional polymorphisms in multidrug resistance 1 gene: correlation with microsatellite instability and lymphoid infiltration in colorectal cancers. J. Med. Genet. (2002) 39:340-346.
  • KURZAWSKI M, DROZDZIK M, SUCHY J etal.: Polymorphism in the P-glycoprotein drug transporter MDR1 gene in colon cancer patients. Eur. J. Clin. Pharmacol. (2005) 61:389-394.
  • HUMENY A, RODEL F, RODEL C et al.: MDR1 single nucleotide polymorphism C3435T in normal colorectal tissue and colorectal carcinomas detected by MALDI-TOF mass spectrometry. Anti-Cancer Res. (2003) 23:2735-2740.
  • SIEGSMUND M, BRINKMANN U, SCHAFFELER E etal.: Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. J. Am. Soc. Nephrol. (2002) 13:1847-1854.
  • MILLER KL, KELSEY KT, WIENCKE JK etal.: The C3435T polymorphism of MDR1 and susceptibility to adult glioma. Neuroepidemiology (2005) 25:85-90.
  • KIMURA Y, SELMI C, LEUNG PS etal.: Genetic polymorphisms influencing xenobiotic metabolism and transport in patients with primary biliary cirrhosis. Hepatology (2005) 41:55-63.
  • PAWLIK A, WRZESNIEWSKA J, FIEDOROWICZ-FABRYCY I, GAWRONSKA-SZKLARZ B: The MDR1 3435 polymorphism in patients with rheumatoid arthritis. Int. J. Clin. Pharmacol. Ther. (2004) 42:496-503.
  • KIVISTO KT, NIEMI M, SCHAEFFELER E etal.: CYP3A5 genotype is associated with diagnosis of hypertension in elderly patients: data from the DEBATE Study. Am. J. Pharmacogenomics (2005) 5:191-195.
  • LENNERNAS H, FAGER G: Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin. Pharmacokinet. (1997) 32:403-425.
  • TOBERT JA: Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat. Rev. Drug Discov. (2003) 2:517-526.
  • TACHIBANA-IIMORI R, TABARA Y, KUSUHARA H etal.: Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab. Pharmacokinet. (2004) 19:375-380.
  • NIEMI M, NEUVONEN PJ, HOFMANN U etal.: Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. Pharmacogenet. Genomics (2005) 15:303-309.
  • HIRANO M, MAEDA M, MATSUSHIMA S, NOZAKI Y, KUSUHARA H, SUGIYAMA Y: Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol. Pharmacol. (2005) 68:800-807.
  • VERSTUYFT C, SCHWAB M, SCHAEFFELER E etal.: Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur. J. Clin. Pharmacol. (2003) 58:809-812.
  • GERLOFF T, SCHAEFER M, JOHNE A etal.: MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br. J. Clin. Pharmacol. (2002) 54:610-616.
  • YI SY, HONG KS, LIM HS etal.: A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. Clin. Pharmacol. Ther. (2004) 76:418-427.
  • DRESCHER S, SCHAEFFELER E, HITZL M etal.: MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br. J. Clin. Pharmacol. (2002) 53:526-534.
  • VON AHSEN N, RICHTER M, GRUPP C, RINGE B, OELLERICH M, ARMSTRONG VW: No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin. Chem. (2001) 47:1048-1052.
  • MIN DI, ELLINGROD VL: C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects. Ther. Drug Monit. (2002) 24:400-404.
  • YATES CR, ZHANG W, SONG P etal.: The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J. Clin. Pharmacol. (2003) 43:555-564.
  • BONHOMME-FAIVRE L, DEVOCELLE A, SALIBA F etal.: MDR-1 C3435T polymorphism influences cyclosporine a dose requirement in liver-transplant recipients. Transplantation (2004) 78:21-25.
  • MACPHEE IA, FREDERICKS S, TAI T etal.: Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirement. Transplantation (2002) 74:1486-1489.
  • ZHENG H, WEBBER S, ZEEVI A etal.: Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am. J. Transplant. (2003) 3:477-483.
  • HAUFROID V, MOURAD M, VAN KERCKHOVE V etal.: The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics (2004) 14:147-154.
  • SIEGMUND W, LUDWIG K, GIESSMANN T etal.: The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin. Pharmacol. Ther. (2002) 72:572-583.
  • ZHANG WX, CHEN GL, ZHANG W etal.: MDR1 genotype do not influence the absorption of a single oral dose of 100 mg talinolol in healthy Chinese males. Clin. Chim. Acta. (2005) 359:46-52.
  • RODRIGUEZ NOVOA S, BARREIRO P, RENDON A etal.: Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C→T polymorphism at the multidrug resistance gene 1. Clin. Infect. Dis. (2006) 42:291-295.
  • PAULI-MAGNUS C, FEINER J, BRETT C etal.: No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects. Clin. Pharmacol. Ther. (2003) 74:487-498.
  • PUTNAM WS, WOO JM, HUANG Y, BENET LZ: Effect of the MDR1 C3435T variant and P-glycoprotein induction on dicloxacillin pharmacokinetics. J. Clin. Pharmacol. (2005) 45:411-421.
  • KERB R, AYNACIOGLU AS, BROCKMOLLER J etal.: The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J. (2001) 1:204-210.
  • YASUI-FURUKORI N, MIHARA K, TAKAHATA T etal.: Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes. Br. J. Clin. Pharmacol. (2004) 57:569-575.
  • HORINOUCHI M, SAKAEDA T, NAKAMURA T etal.: Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin. Pharm. Res. (2002) 19:1581-1585.
  • ANGLICHEAU D, VERSTUYFT C, LAURENT-PUIG P etal.: Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J. Am. Soc. Nephrol. (2003) 14:1889-1896.
  • ROBERTS RL, JOYCE PR, MULDER RT, BEGG EJ, KENNEDY MA: A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J. (2002) 2:191-196.
  • BRUMME ZL, DONG WW, CHAN KJ etal.: Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response. AIDS (2003) 17:201-208.
  • ALONSO-VILLAVERDE C, COLL B, GOMEZ F etal.: The efavirenz-induced increase in HDL-cholesterol is influenced by the multidrug resistance gene 1 C3435T polymorphism. AIDS (2005) 19:341-342.
  • ZHENG H, WEBBER S, ZEEVI A etal.: The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. Hum. Immunol. (2002) 63:765-770.
  • KOTRYCH K, DOMANSKI L, GORNIK W, DROZDZIK M: MDR1 gene polymorphism in allogeenic kidney transplant patients with tremor. Pharmacol. Rep. (2005) 57:241-245.
  • ZHENG HX, ZEEVI A, MCCURRY K etal.: The impact of pharmacogenomic factors on acute persistent rejection in adult lung transplant patients. Transpl. Immunol. (2005) 14:37-42.
  • KAFKA A, SAUER G, JAEGER C etal.: Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int. J. Oncol. (2003) 22:1117-1121.
  • BABAOGLU MO, BAVAR B, AYNACIOGLU AS etal.: Association of the ABCB1 3435C > T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists. Clin. Pharmacol. Ther. (2005) 78:619-626.
  • YASUI-FURUKORI N, SAITO M, NAKAGAMI T, KANEDA A, TATEISHI T, KANEKO S: Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study. Prog. Neuropsychopharmacol. Biol. Psychiatry (2006) 30(2):286-291.
  • MORIMOTO K, UEDA S, SEKI N etal.: Candidate gene approach for the study of genetic factors involved in HMG-CoA reductase inhibitor-induced rhabdomyolysis. 18th JSSX annual meeting. Sapporo, Japan. 8PE-32 (2003).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.